CON
Concentra Group Holdings Parent, Inc.19.55
-0.33-1.66%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A reaffirms guide, details organic drivers
Q&A largely reaffirmed prepared remarks on 2025 beats and 2026 guidance, brushing off weather or respiratory drags on Q1 volumes as immaterial. Management credited sales tech and AI for customer retention and penetration as main drivers of organic volume growth—3% in workers' comp, 2% in employer services—beyond de novos' <1% contribution. They detailed New York fee schedule push for PT codes alongside E&M hikes, poised for quick de novo entry. Labor stays stable at 2-3% inflation, with falling turnover. Separation costs net neutral in guide. Confident tone prevails; watch tech-fueled share gains.
Key Stats
Market Cap
2.51BP/E (TTM)
16.71Basic EPS (TTM)
1.17Dividend Yield
0.01%Recent Filings
8-K
Q4 revenue +15.9%, EBITDA +22.9%
Concentra crushed Q4 with revenue up 15.9% to $539.1M and Adjusted EBITDA surging 22.9% to $95.3M, driven by 9.0% higher patient visits and 3.1% revenue per visit lift. Full-year revenue hit $2.16B, up 13.9%, with onsite clinics ballooning to 411 from 157 via acquisitions. Board declared $0.0625/share dividend; 2026 guides $2.25B-$2.35B revenue. Leverage dipped to 3.4x.
10-K
FY2025 results
Concentra drove FY2025 revenue to $2.2B, up 13.9% y/y, fueled by Nova's 67 centers added in Q1 and Pivot Onsite's 240 clinics in Q2, alongside 7.7% organic VPD growth to 53k and 4.3% revenue/visit lift to $147. Yet margins held firm at 20.0% Adjusted EBITDA. Q4 accelerated with acquisition integration and fee schedule gains, while voluntary $85M revolver paydown left $428M available. Share repurchases hit $20M under the new $100M program. Labor shortages threaten quarterly momentum.
8-K
Concentra beats 2025 guidance
Concentra released preliminary Q4 and FY 2025 results on January 28, 2026, beating prior guidance with revenue up 15.9% to $539.1M in Q4 and 13.9% to $2.16B for the year, driven by 9.0% higher visits per day and 3.1% revenue per visit, plus onsite clinics surging to 411 from 157. Adjusted EBITDA climbed 22.9% to $95.3M in Q4 and 14.6% to $431.9M yearly. Growth accelerates. 2026 guides $2.25B-$2.35B revenue, $450M-$470M Adjusted EBITDA.
8-K
Q4 metrics, FY25 guidance out
Concentra released preliminary Q4 2025 operational metrics and FY 2025 guidance of $2.145bn–$2.160bn revenue and $425mm–$430mm Adjusted EBITDA, projecting 13% YoY growth YTD through September. TTM Adjusted EBITDA hit $414mm at 19.8% margin, with 108% free cash flow conversion and 13.5% ROIC. Strong margins persist despite public costs.
8-K
Execs awarded restricted stock
IPO
Website
Employees
Sector
Industry
CCM
Concord Medical Services Holdin
4.33-0.22
HCA
HCA Healthcare, Inc.
469.79-7.19
LFST
LifeStance Health Group, Inc.
6.88-0.04
MD
Pediatrix Medical Group, Inc.
22.32-0.37
NUTX
Nutex Health Inc.
171.72-4.06
PNTG
The Pennant Group, Inc.
29.73+0.00
SEM
Select Medical Holdings Corpora
15.27-0.37
SYRA
Syra Health Corp.
0.07+0.01
THC
Tenet Healthcare Corporation
196.88-0.44
USPH
U.S. Physical Therapy, Inc.
78.50-2.65